Ayuda
Ir al contenido

Dialnet


Resumen de Microparticulas de poli-esteres para inmunoterapia en alergias

Beatriz San Ramón Aberasturi

  • #TITULO: MICROPARTICULAS DE POLI-ESTERES PARA INMUNOTERAPIA EN ALERGIAS #RESUMEN: MICROPARTICLES OF POLY-ESTERS FOR IMMUNOTHERAPY IN ALLERGY Polymeric microparticles appear as a novel strategy for the administration of allergens, avoiding the periodical injections required in the subcutaneous immunotherapy. Beside, the carrier protects the allergen from degradation and allows the co-encapsuiation of immunoadjuvants, such as cpG sequences. in this work, poly-epsilon-caprolactone and poíy (lactic-co-glycolic) acid 502 and 756 have been selected to fabricate micro particles, obtaining high encapsulation efficiencies of ovalbumin (OVA), used as allergen model. in the same way, PLGA microparticles demonstrated their potential as CpG carriers, complexed either with chitosan or dotap. Regardinq the immune response after intradermal administration, the co-encapsulation or both the oligonucleotide and the allergen resulted in an increase of the Thl profile when the administration of the microencapsulated allergen in absence of CpG sequences induced the production of high leveis of igG2a (PLGA 502). However, no benefits were observed when CpG motifs were co-encapsulated along with the allergen if the microparticles containing only ova potentated a strong Thl response (PLGA 756). Finally, igE and igGl levéis detected for the allergen into microparticles were lower than those obtained in animais treated with the soluble forms of the allergen. in the anaphylactic episode, it is noteworthing that the administration of the allergen encapsulated reduced the mortality, especially in the case of microparticles of OVA and CpG sequences associated with DOTAP (100% survival). Despite the immunological mechanisms involved in this processes are still unknown, the combination of allergen and CpG sequences into microparticles could be a safe and efficient alternative for the current treatments in immunotherapy


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus